Skip to main content
S&P 5007,805.45-0.02%DOW51,670.10-0.35%NASDAQ27,204.38-0.15%BTC$83,354.00+0.97%ETH$2,506.79+0.74%GOLD$4,184.50+0.17%OIL$94.76+0.66%
Smart Investors Daily
SID Premium
AR

NASDAQ · ARTV

Artiva Biotherapeutics, Inc.

Healthcare · Biotechnology

$6.77

Down-$0.48 (-7.09%)

Updated Oct 13, 2026, 10:22 PM

SID Score

5.1/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
142.85M
P/E ratio
-1.97
Dividend yield
0.00%
52-week range
$4.74 – $14.53
Volume
248.58K
Avg. volume
1.03M

Price performance · ARTV

ARTV price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 12, 2026

ARTV closed at $6.77 after 21 trading sessions, down 33.23% for the selected period.

Last close
$6.77
Period change
-33.23%
Period low
$6.77
Period high
$10.14
Daily close
View OHLC price history
ARTV OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 12, 2026$6.92$6.943$6.73$6.77248.58K
Oct 9, 2026$6.84$7.135$6.77$6.94275.94K
Oct 8, 2026$6.89$6.92$6.575$6.80339.71K
Oct 7, 2026$7.10$7.27$6.84$7.00324.58K
Oct 6, 2026$7.12$7.38$6.92$7.27665.42K
Oct 5, 2026$6.75$7.16$6.5195$7.13473.19K
Oct 2, 2026$6.89$7.00$6.74$6.83587.65K
Oct 1, 2026$7.11$7.15$6.77$6.79444.37K
Sep 30, 2026$7.10$7.40$6.96$7.12383.98K
Sep 29, 2026$7.06$7.18$6.92$7.03450.57K
Sep 28, 2026$6.91$7.185$6.75$7.05437.53K
Sep 25, 2026$7.48$7.49$6.90$6.99507.14K
Sep 24, 2026$7.62$7.71$7.22$7.49511.72K
Sep 23, 2026$7.99$8.20$7.52$7.72407.79K
Sep 22, 2026$7.87$8.39$7.855$8.09437.98K
Sep 21, 2026$8.63$8.64$7.78$7.83629.42K
Sep 18, 2026$8.45$8.75$8.40$8.612.21M
Sep 17, 2026$8.66$8.72$8.35$8.44456.52K
Sep 16, 2026$8.89$9.03$8.485$8.60516.99K
Sep 15, 2026$10.05$10.05$8.84$8.91584.58K
Sep 14, 2026$10.21$10.55$10.13$10.14243.87K

Latest ARTV news

The latest Smart Investors Daily articles mentioning ARTV.

Stock researchCompany · Overview

ARTV research

Overview

Company profile and research snapshot.

Company profile

Artiva Biotherapeutics Inc is a biopharmaceutical company. The company is engaged in advancing a pipeline of off-the-shelf, allogeneic NK cell therapies for the treatment of hematologic malignancies or solid tumors. The pipeline program of the company includes Artiva-Funded Trials and Collaborator-Funded Trials. The company pipeline includes AlloNK: is an allogeneic, off-the-shelf, cryopreserved NK cell therapy candidate designed to enhance the antibody-dependent cellular cytotoxicity (ADCC) effect of mAbs to drive B-cell. Others products includes: CAR-NK(AB201),CAR-NK(AB205).

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$20.50
Implied upside
—
Analysts
12
ARTV recent ratings
DateFirmRatingTarget
Oct 2, 2026Cantor FitzgeraldOverweight—
Jun 8, 2026NeedhamBuy—
May 12, 2026NeedhamBuy—
May 11, 2026Cantor FitzgeraldOverweight—
May 11, 2026WedbushOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 2, 2026

Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at the American College of Rheumatology (ACR) Convergence 2026

Oral presentation highlighting updated clinical data from at least 20 patients with refractory rheumatoid arthritis (RA), 11 patients with Sjögren disease (SjD) and at least five patients with systemic sclerosis (SSc) treated with AlloNK plus rituximab in the ongoing Phase 2a basket trial, all with at least six months of follow-upPoster presentation highlighting deep, consistent B-cell depletion comparable to that observed with CD19 CAR T-cell therapies and a favorable tolerability profile acros

Yahoo · Oct 1, 2026

Artiva Biotherapeutics Highlights Updated AlloNK® Data in Sjögren Disease Presented at the 17th International Symposium on Sjögren’s Disease (ISSjD 2026)

Oral presentation includes safety and efficacy data as of the July 2, 2026 data cutoff, highlighting clinically meaningful improvements in disease activity and symptoms at six months in 11 patients with longstanding, highly active Sjögren diseaseMean stimulated salivary flow increased from 0.4 to 1.1 mL/min among eight patients with baseline hyposalivation and available six-month dataUpdated safety data across 73 Phase 2a basket study patients support the potential for outpatient administration,

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By